Dell Precision Medicine Program
“This is what we want for every patient. We shouldn’t just be waiting until a child is told they are incurable to investigate the best ways to personalize treatment.”Dr Giselle Sholler
The launch of a new clinical trial called PEDS-PLAN in September of 2015 marks a paradigm shift in childhood cancer treatment and precision medicine — the first time DNA and RNA sequencing are being done in newly diagnosed patients.
Personalized medicine… precision medicine… molecularly guided therapy (MGT)… genomics. They’re different terms for what is generally the same concept — personalizing treatment per patient based on specific genetic or molecular analysis. In childhood cancer, genomics is being used to beat cancer on a kid by kid basis.
Abstracts and Publications
Feasibility Published Paper
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med. 2015 Feb 26. doi: 10.1002/cam4.436. [Epub ahead of print]
View on PubMed.
A Pilot Trial Testing the Feasibility of using Molecular-Guided Therapy in Patients with Refractory or Recurrent Neuroblastoma. April 2011 AACR Annual Meeting, Orlando, Fl
View on AACR.
A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma. American Association for Cancer Research Annual Meeting April 2013. Washington, DC AND American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting May 2014. Chicago, IL
View on ASPHO.
The Signature Study: Molecular Analysis of Pediatric Tumors with Establishment of Tumor Models in a Biology Study, American Association for Cancer Research (AACR) Annual Meeting, April, 2017, Washington, DC
View on Google.